Active, not recruitingPhase 3NCT05673902
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
Studying Idiopathic recurrent pericarditis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- R-Pharm International, LLC
- Principal Investigator
- Mikhail SamsonovR-Pharm
- Intervention
- RPH-104(biological)
- Enrollment
- 17 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (1)
- National medical research center named after V. A. Almazov, Saint Petersburg, Russia
Collaborators
R-Pharm · Unimed Laboratories · Data Management 365 · Exacte Labs LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05673902 on ClinicalTrials.gov